43 results about "Lipid matrix" patented technology

The invention relates to a process for the manufacture of a pharmaceutical composition with modified release of active principle comprising at least one active principle, a lipid matrix agent composed of ester of alcohol with at least one fatty acid and at least one adjuvant.This process is characterized in that:a powder composed of at least one component selected in the group comprising the active principle and the adjuvant, is mixed, while heating and fluidizing, in order to obtain individual grains;the said lipid matrix agent is liquefied separately under warm conditions;the said powder is then coated under warm conditions by spraying the said lipid matrix agent over the individual grains;finally, the temperature of the combined product is lowered in order to allow the lipid matrix agent to solidify.

The present invention is in the area of administration forms and delivery systems for drugs, vaccines and other biologically active agents. More specifically the invention is related to the preparation of suspensions of colloidal solid lipid particles (SLPs) of predominantly anisometrical shape with the lipid matrix being in a stable polymorphic modification and of suspensions of micron and submicron particles of bioactive agents (PBAs); as well as to the use of such suspensions or the lyophilizates thereof as delivery systems primarily for the parenteral administration of preferably poorly water-soluble bioactive substances, particularly drugs, and to their use in cosmetic, food and agricultural products. SLPs and PBAs are prepared by the following emulsification process: (1) A solid lipid or bioactive agent or a mixture of solid lipids or bioactive agents is melted. (2) Stabilizers are added either to the lipid or bioactive agent and to the aqueous phase or to the aqueous phase only depending on their physicochemical characteristics. Stabilizers may also be added or exchanged after homogenization. (3) Drugs or other bioactive substances to be incorporated into the SLPs may be melted together with the lipids if the physicochemical characteristics of the substance permit or may be dissolved, solubilized or dispersed in the lipid melt before homogenization. (4) The aqueous phase is heated to the temperature of the melt before mixing and may contain for example stabilizers, isotonicity agents, buffering substances, cryoprotectants and / or preservatives. (5) The molten lipid compounds and the bioactive agents are emulsified in an aqueous phase preferably by high-pressure homogenization.

A method for enhancing the oral bioavailability of a prodrug ester by formulating the ester as a non-emulsified formulation with lecithin; as well as a pharmaceutical composition of at least one antibiotic and lecithin in a non-emulsified formulation; a method of treating infections with the non-emulsified formulation, and a method for preparing tablets by direct compression of blends of drugs with lecithin are disclosed. Non-emulsified formulations include solids, tablets, capsules, lozenges, suspensions, elixirs and solutions, and exclude emulsions, liposomes, lipid matrix systems and micro-emulsions. A suitable prodrug ester is a cephalosporin β-lactam antibiotic such as cefditoren pivoxil, and a suitable non-emulsified formulation is a solid formulation.

The present invention relates to a composition for use in animal nutrition comprising a controlled release matrix and to a method for preparing said composition. Moreover, the present invention relates to a method for the treatment of monogastric animals in which said composition is used as addition of active substances such as for instance organic acids and / or inorganic acids for preserving and acidifying food for monogastric animals, including swine, sheep, rabbits, birds, horses, pets and humans.

In alternative embodiments, the invention provides phosphatidylinositol-specific phospholipase C (PI-PLC) enzymes, nucleic acids encoding them, antibodies that bind specifically to them, and methods for making and using them. Industrial methods and products comprising use of these phospholipases are also provided. In certain embodiments, provided herein are methods for hydration of non hydratable phospholipids (NHPs) within a lipid matrix. The methods enable migration of NHPs to an oil-water interface thereby allowing the NHPs to be reacted and / or removed from the lipids. In certain embodiments, provided is a method for removing NHPs, hydratable phospholipids, and lecithins from vegetable oils to produce a degummed oil or fat product that can be used for food production and / or non-food applications. In certain embodiments, provided herein are methods for hydration of NHPs followed by enzymatic treatment and removal of various phospholipids and lecithins. The methods provided herein can be practiced on either crude or water-degummed oils.

A composition and a method of producing a composition which simulates hydration, cleansing and other properties of native vernix. The composition contains hydrated synthetic cells in a lipid matrix to provide rheological properties which are substantially similar to those of native vernix, and may also contain proteins. In one embodiment, the composition contains cubosomes / water with up to 30% protein and about 5% lipid to about 30% lipid. The composition may be used to cleanse newborn skin, compromised skin surfaces, as well as normal skin, to provide hydration / barrier function, and other applications.

The present invention relates to novel nanocell compositions and their use in imaging, diagnostic and treatment methods. In one embodiment, nanocells tailored for imaging methods comprise a nanocore surrounded by a lipid matrix, and are modified to contain a radionuclide core or a nanocore with an emission spectra. The nanocells may be size restricted such as being greater than about 60 nm so that they selectively extravasate at sites of angiogenesis (e.g. tumor) and do not pass through normal vasculature or enter non-tumor bearing tissue. In this way, angiogenic sites can be both detected and treated. In another embodiment, nanocells are tailored for various treatment methods, including the treatment of brain cancer, asthma, Grave's Disease, Cystic Fibrosis, and Pulmonary Fibrosis.

The present invention is generally related to the discovery of the use of a novel composition (Ri-Active™), containing a concentrate of the bioactives, micronutrients and antioxidants present in the unsaponifiable fraction of rice bran oil or rice germ oil, in the prevention and treatment of health disorders. The novel use of the by-products of rice bran oil or rice germ (and other vegetable oils) industries directly after purification and stabilization for therapeutic purposes is a unique and innovative approach that has been proved in the pilot study conducted by the current inventors. The current inventors have pioneered a new approach to prevent and treat health disorders such as cardiovascular diseases, hypercholesterolemia and diabetes which is both effective and inexpensive. The proprietary technology developed by the current inventors to produce Ri-Active™ from rice bran oil by-products or rice germ is very different from others who use these by-products to either isolate or purify individual micronutrients of value for use in other nutraceutical formulations. Most of the by-products of the edible oil refining industry are either discarded or sold at a throw away cost to the soap industry for their free fatty acid content. The novel technology and approach developed by the current inventors to utilize these low cost by-products from the edible oil refining industry and produce a highly effective therapeutic product has yielded a new and valuable use for these materials. This invention extends to the uses (therapeutic usefulness) and cost effectivity of similar whole extract concentrates of unsaponifiable micronutrients prepared from other vegetable oils rich in unsaponifiable fractions. The current discovery specifically covers the uses of Ri-Active™ (derived either from rice bran oil or rice germ oil), in preventing or treating cardiovascular disease, diabetes, hyperlipidemia, hypercholesterolemia and arteriosclerosis. Ri-Active™ contains many unsaponifiable bioactives and antioxidants of rice bran and rice germ in very high concentrations in a natural lipid matrix. These constituents in their natural lipid matrix act synergistically in the treatment of cardiovascular disease and other disorders and therefore the whole extract concentrate containing these constituents is far more efficacious than administering a mixture of procured ingredients in similar concentrations. The efficacy of this novel composition (Ri-Active™) in the treatment of cardiovascular disease risk factors has been proved in the pilot animal study conducted by the current inventors. Ri-Active™ has been tested to be safe, and highly effective in small doses.

The invention relates to an anhydrous multiphase gel system consisting of an outer lipid matrix and of an inner phase gelled by means of polymer, obtained by: a) melting the lipid phase while forming a liquid lipid phase; b) mixing and homogenizing polymers or polymer blends that are capable of swelling while forming a polymer phase to be dispersed; combining the polymer phase with the liquid lipid phase and homogenizing the phases, and; d) cold stirring the phase mixture until forming a solid gel-like mixed structure of the entire system. The anhydrous multiphase gel system is particularly suited for accommodating poorly soluble active substances in high concentrations and for topical and transdermal applications. The described system is characterized as an EDRS Entrapped Drug Reservoir System .

The present invention relates to methods and compositions for lipid matrix-assisted chemical ligation and synthesis of membrane polypeptides that are incorporated in a lipid matrix. The invention is exemplified in production of a prefolded membrane polypeptide embedded within a lipid matrix via stepwise chemoselective chemical ligation of unprotected peptide segments, where at least one peptide segment is embedded in a lipid matrix. Any chemoselective reaction chemistry amenable for ligation of unprotected peptide segments can be employed. Suitable lipid matrices include liposomes, micelles, cell membrane patches and optically isotropic cubic lipidic phase matrices. Prefolded synthetic and semi-synthetic membrane polypeptides synthesized according to the methods and compositions of the invention also permit site-specific incorporation of one or more detectable moieties, such as a chromophore, which can be conveniently introduced during synthesis. The methods and compositions of the invention have multiple uses. For example, they can be used to assay ligand binding to membrane polypeptides and domains comprising a receptor, and thus are extremely useful for structure / function studies, drug screening / selection / design, and diagnostics and the like, including high-throughput applications. The methods and compositions of the invention are particularly suited for FRET analyses of previously inaccessible membrane polypeptides.

A semi-solid controlled release composition containing biocompatible and bioerodible semi-solid lipid matrix incorporating local anesthetics agents to form a semi-solid solution arsd the methods of manufacturing are disclosed.

Methods for hydrolyzing solid ungranulated lysophosphatidylcholine with phospholipase A2 are provided. Also disclosed are methods for making a lipid matrix of lysophosphatidylcholine, monoglyceride and fatty acid, and lipid matrices of particular structure.

The invention discloses a cation gene carrier-constructed niosomes cation gene carrier with excellent performance such as high transfection and low toxicity, obtained by combining a commonly used activity polymerization method based on lipids (cholesterol, phosphatidylinositol and the like). A method is easy and feasible, a polymerization method ensures effective controllable molecular weight, compared with a common cation gene carrier, the gene carrier has a characteristic of being effectively compatible with a cytomembrane by a lipid matrix, or a characteristic of establishing into lipidosome per se to increase intake of cells, so the transfection efficiency of the cells is increased. The cation gene carrier of a series of niosomes constructed by the method has well transfection efficiency in cell lines of HepG2, COS7, C6, SL, H9C2 and the like, the transfection efficiency is higher than the transfection efficiency of the internationally commercially used lipidosome lipfect2000, and the niosomes cation gene carrier effectively solves the difficult problem of poorer in-vivo transfection efficiency of the lipidosome lipfect2000, and has higher commercial potential.

The present invention provides solid dispersion, comprising: 20-O-β-D-glucopyranosyl-20(S)-protopanaxadiol which is a pharmacologically active ingredient; and a saturated polyglycolized glyceride which is a lipid matrix. The solid dispersion of the present invention has effects of increasing dissolution rate of 20-O-β-D-glucopyranosyl-20(S)-protopanaxadiol.